LUC00092I2 - - Google Patents

Download PDF

Info

Publication number
LUC00092I2
LUC00092I2 LU00092C LUC00092C LUC00092I2 LU C00092 I2 LUC00092 I2 LU C00092I2 LU 00092 C LU00092 C LU 00092C LU C00092 C LUC00092 C LU C00092C LU C00092 I2 LUC00092 I2 LU C00092I2
Authority
LU
Luxembourg
Application number
LU00092C
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of LUC00092I1 publication Critical patent/LUC00092I1/fr
Publication of LUC00092I2 publication Critical patent/LUC00092I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
LU00092C 2007-02-23 2018-11-13 LUC00092I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89140907P 2007-02-23 2007-02-23
PCT/US2008/002333 WO2008103432A1 (fr) 2007-02-23 2008-02-21 Anticorps obtenus par génie génétique dirigés contre l'il-23p19

Publications (2)

Publication Number Publication Date
LUC00092I1 LUC00092I1 (fr) 2018-11-15
LUC00092I2 true LUC00092I2 (fr) 2019-12-24

Family

ID=39592753

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00092C LUC00092I2 (fr) 2007-02-23 2018-11-13

Country Status (30)

Country Link
US (3) US8293883B2 (fr)
EP (2) EP2059534B1 (fr)
JP (5) JP2010518856A (fr)
KR (1) KR101520110B1 (fr)
CN (1) CN101687925B (fr)
AR (1) AR065420A1 (fr)
AT (1) ATE554791T1 (fr)
AU (1) AU2008218968B2 (fr)
BR (1) BRPI0807710B1 (fr)
CA (1) CA2678749C (fr)
CY (3) CY1112912T1 (fr)
DK (2) DK2059534T3 (fr)
ES (2) ES2708988T3 (fr)
FR (1) FR18C1051I2 (fr)
HR (2) HRP20120611T1 (fr)
HU (2) HUE042172T2 (fr)
IL (1) IL200560A (fr)
LT (2) LT2426144T (fr)
LU (1) LUC00092I2 (fr)
MX (1) MX2009009079A (fr)
NL (1) NL300959I2 (fr)
NO (1) NO2018040I1 (fr)
NZ (1) NZ579158A (fr)
PL (2) PL2059534T3 (fr)
PT (2) PT2426144T (fr)
RS (2) RS58098B1 (fr)
SI (2) SI2059534T1 (fr)
TR (1) TR201821029T4 (fr)
WO (1) WO2008103432A1 (fr)
ZA (1) ZA200906224B (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2452694T (pt) 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
IN2014DN10515A (fr) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
EP2044118A2 (fr) 2006-06-13 2009-04-08 Zymogenetics, Inc. Antagonistes d'il-17 et d'il-23 et leurs procédés d'utilisation
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
PL2059534T3 (pl) * 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
HRP20150512T1 (hr) 2007-09-04 2015-06-19 Compugen Ltd. Polipeptidi i polinukleotidi, te njihova uporaba kao ciljnih molekula za proizvodnju lijekova i bioloških sredstava
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
CN102202655B (zh) 2008-08-27 2013-06-19 默沙东公司 基因工程抗IL-23p19抗体的冻干制剂
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
AU2009327411A1 (en) 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Feed supplement for mammalian cell culture and methods of use
KR101048593B1 (ko) 2009-02-27 2011-07-12 씨제이제일제당 (주) 메칠머캅탄과 디메칠설파이드의 혼합물을 사용하여 메치오닌 생산능을 증가시키는 방법
KR101164711B1 (ko) 2009-02-27 2012-07-11 씨제이제일제당 (주) 미네랄 첨가와 산처리를 이용하여 메치오닌의 용해도를 증가시키는 방법
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
EP2409991B1 (fr) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Variant d'une région constante d'anticorps
US20120269765A1 (en) * 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
US8283152B2 (en) 2009-08-28 2012-10-09 Cj Cheiljedang Corporation Microorganism producing O-acetyl-homoserine and the method of producing O-acetyl-homoserine using the microorganism
US8609396B2 (en) 2009-08-28 2013-12-17 Cj Cheiljedang Corporation Microorganism producing O-acetyl-homoserine and the method of producing O-acetyl-homoserine using the microorganism
WO2011033493A1 (fr) * 2009-09-21 2011-03-24 Conservatoire National des Arts et Métiers Conjugués porteurs de peptides il-23 et leurs anticorps induits
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
BR112012019881A2 (pt) * 2010-02-18 2017-06-27 Bristol Myers Squibb Co proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
DE112012000404T5 (de) 2011-01-04 2014-04-17 Charitè Universitätsmedizin Berlin Modulatoren von IL-12 und/oder IL-23 zur Prävention oder Behandlung des Morbus Alzheimer
WO2013001517A1 (fr) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides et leurs utilisations pour traiter les troubles auto-immuns et l'infection
EP2583979B1 (fr) * 2011-10-19 2015-12-16 Effimune Méthodes de preparation d'anticorps dirigés contre la sous-unité p19 de l'IL-23 humaine
US9617336B2 (en) 2012-02-01 2017-04-11 Compugen Ltd C10RF32 antibodies, and uses thereof for treatment of cancer
NZ700802A (en) * 2012-05-03 2017-06-30 Boehringer Ingelheim Int Anti-il-23p19 antibodies
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
CZ2012829A3 (cs) 2012-11-23 2014-06-11 Biotechnologický Ústav Av Čr, V.V.I. Polypeptidy pro léčbu autoimunitních chorob založenou na blokaci receptoru pro lidský cytokin IL-23
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US20150307606A1 (en) * 2012-12-13 2015-10-29 Ashwin Basarkar Lyophilized spherical pellets of anti-il-23 antibodies
AR094877A1 (es) * 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
WO2014143540A1 (fr) 2013-03-15 2014-09-18 Amgen Inc. Méthodes de traitement de la maladie de crohn à l'aide d'un anticorps anti-il-23
RS62633B1 (sr) 2013-03-15 2021-12-31 Protagonist Therapeutics Inc Analozi hepcidina i njihove primene
EP3689369A1 (fr) 2013-03-15 2020-08-05 Amgen, Inc Procédés pour le traitement du psoriasis à l'aide d'un anticorps anti-il-23
CA2891557A1 (fr) * 2013-03-26 2014-05-22 Pieris Ag Nouveaux polypeptides de liaison specifique et leurs utilisations
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
SG10201912019WA (en) 2014-05-22 2020-02-27 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
CN107206254B (zh) * 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
EP3708679A1 (fr) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarqueurs utiles dans le traitement de maladies liées à l'il-23a
MY198017A (en) * 2014-08-19 2023-07-26 Merck Sharp & Dohme Anti-tigit antibodies
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
WO2016054411A1 (fr) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOUVEAUX ANTAGONISTES PEPTIDIQUES MONOMÈRES ET DIMÈRES DE α4β7
WO2016054445A1 (fr) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Nouveaux peptides monomères et dimères cycliques possédant une activité antagoniste de l'intégrine
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
IL321788A (en) 2015-02-04 2025-08-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
EP3391905A1 (fr) 2015-04-14 2018-10-24 Boehringer Ingelheim International GmbH Traitement de l'asthme avec anticorps contre il-23a
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
RU2018113694A (ru) 2015-09-17 2019-10-17 Эмджен Инк. Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
CA3009834A1 (fr) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues de mimetiques d'hepcidine a demi-vie in vivo amelioree
WO2017165676A1 (fr) 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. Procédés de synthèse d'antagonistes de peptide α4β7
US20170298126A1 (en) 2016-04-15 2017-10-19 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
WO2018071455A1 (fr) 2016-10-10 2018-04-19 Cellerant Therapeutics, Inc. Dimères d'isoquinolidinobenzodiazépine (iqb)-1(chlorométhyl)-2,3-dihydro-1h-benzo[e]indole (cbi)
EP3848390A1 (fr) 2016-10-14 2021-07-14 Boehringer Ingelheim International GmbH Procédés de traitement de maladies
WO2018071910A2 (fr) * 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anticorps anti-il1-rap
US11359025B2 (en) 2016-10-16 2022-06-14 Cantargia Ab Anti-IL1-RAP antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
EP4092038A1 (fr) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Peptides d'agoniste opioïde et leurs utilisations
EP4501952A3 (fr) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Mimétiques d'hepcidine conjugués
TWI744617B (zh) 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
EP3820883A4 (fr) 2018-07-12 2022-04-20 Protagonist Therapeutics, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
CN112689643A (zh) 2018-07-13 2021-04-20 阿斯特捷利康合作创业有限责任公司 用布雷库单抗治疗溃疡性结肠炎
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
KR20210096559A (ko) * 2018-11-27 2021-08-05 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 항IL-23p19 항체 및 이의 용도
EP3952993B1 (fr) 2019-04-12 2025-01-08 Almirall S.A. Procédé de traitement du psoriasis en plaques résistant aux esters d'acide fumarique
MX2021012652A (es) * 2019-04-15 2022-01-24 Sun Pharmaceutical Ind Ltd Metodos para el tratamiento de sujetos con artritis psoriasica.
CN116082455A (zh) 2019-07-10 2023-05-09 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
EP4062933A4 (fr) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Préparation pharmaceutique comprenant un anticorps
CA3164996A1 (fr) 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anticorps anti-interleukine-23 p19 et leurs methodes d'utilisation
EP4090669A4 (fr) 2020-01-15 2024-11-20 Janssen Biotech, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
SI4090670T1 (sl) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni zaviralci receptorja interlevkina-23 in njihova uporaba za zdravljenje vnetnih bolezni
WO2021201276A1 (fr) 2020-04-03 2021-10-07 株式会社 メドレックス Arn double brin inhibant particulièrement l'expression d'il-23, et composition pharmaceutique le comprenant
KR102481026B1 (ko) * 2020-04-22 2022-12-22 한양대학교 산학협력단 인터루킨 23의 항체를 포함하는 화학요법유발 말초신경병증의 예방 또는 치료용 약학적 조성물
CN112807428B (zh) * 2020-06-12 2024-08-27 江苏荃信生物医药股份有限公司 包含抗人白介素23单克隆抗体的药物组合物
TWI904235B (zh) 2020-09-10 2025-11-11 美商美國禮來大藥廠 治療性抗體調配物
IL316550A (en) 2020-11-20 2024-12-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
US20240254217A1 (en) 2021-05-28 2024-08-01 Eli Lilly And Company Anti -il-23p19 antibody regulation of genes involved in ulcerative colitis
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Peptide inhibitors linked to fatty residues of the interleukin-23 receptor
EP4410841A4 (fr) * 2021-09-30 2025-08-13 Jiangsu Hengrui Pharmaceuticals Co Ltd Protéine de fusion d'anticorps anti-il23 et ses utilisations
EP4409298A1 (fr) 2021-09-30 2024-08-07 Eli Lilly and Company Régulation d'anticorps anti-il-23p19 de gènes impliqués dans l'urgence intestinale dans la colite ulcéreuse
CN119095617A (zh) 2022-01-25 2024-12-06 太阳医药工业有限公司 用于治疗患有头皮斑块型银屑病的受试者的方法
WO2024077113A1 (fr) 2022-10-06 2024-04-11 Eli Lilly And Company Méthodes de traitement de la fatigue liée à la colite ulcéreuse
KR20250152080A (ko) 2023-02-22 2025-10-22 일라이 릴리 앤드 캄파니 궤양성 결장염에서의 유전자의 조절 및 그의 용도
US20240391993A1 (en) * 2023-05-25 2024-11-28 Sun Pharmaceutical Industries Limited Methods and compositions for treating plaque psoriasis
WO2025083549A1 (fr) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Méthodes et combinaisons d'inhibiteurs de la voie il-23 et de modulateurs de la voie de signalisation s1p pour le traitement de maladies auto-immunes
WO2025109545A1 (fr) * 2023-11-23 2025-05-30 Sun Pharmaceutical Industries Limited Procédés de production de protéines recombinantes
US20250228864A1 (en) 2023-11-29 2025-07-17 Gilead Sciences, Inc. Therapies for the treatment of inflammatory bowel disease
WO2025120601A1 (fr) 2023-12-06 2025-06-12 Sun Pharmaceutical Industries Limited Méthodes et compositions pour traiter le psoriasis des ongles

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (fr) 1990-01-19 1991-07-24 Merck & Co. Inc. Méthode de production d'immunoglobulines recombinantes
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
EP1498427B1 (fr) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulines dépourvus de chaînes légères
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
DE69942607D1 (de) 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
EP1942114A3 (fr) 1999-03-11 2008-08-27 Schering Corporation "Cytokines de mammifères ; réactifs et procédés associés"
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
HK1044170B (en) 1999-09-09 2008-08-01 Merck Sharp & Dohme Corp. Mammalian interleukin-12 p40 and interleukin b30. combinations thereof. antibodies. uses in pharmaceutical compositions
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
EP2108660A1 (fr) 2002-10-30 2009-10-14 Genentech, Inc. Inhibition de la production d'il-17
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
SI1601694T1 (sl) 2003-03-10 2010-01-29 Schering Corp Uporabe IL-23 antagonistov; sorodni reagenti
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
WO2005044853A2 (fr) 2003-11-01 2005-05-19 Genentech, Inc. Anticorps anti-vegf
CN101979650B (zh) 2003-10-22 2015-09-16 凯克研究生院 使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法
WO2005047328A2 (fr) 2003-11-07 2005-05-26 Curagen Corporation Anticorps diriges contre l'inhibiteur de la protease des leucocytes secreteurs
PE20050925A1 (es) 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP2292758A3 (fr) * 2004-12-20 2013-12-25 Merck Sharp & Dohme Corp. Utilisations de cytokine de mammifère, réactifs associés
EP3520815B1 (fr) 2005-02-08 2021-11-17 Genzyme Corporation Anticorps de tgfbeta
PT2452694T (pt) 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
AU2006283194B9 (en) 2005-08-25 2011-02-03 Eli Lilly And Company Anti-IL-23 Antibodies
LT1931710T (lt) 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
EP2044118A2 (fr) * 2006-06-13 2009-04-08 Zymogenetics, Inc. Antagonistes d'il-17 et d'il-23 et leurs procédés d'utilisation
PL2059534T3 (pl) * 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
CA2683145C (fr) 2007-04-27 2018-06-12 Katherine E. Lewis Antagonistes a il-17a, il-17f et il-23p19, et procedes d'utilisation de ceux-ci
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
WO2009082624A2 (fr) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonistes de il-17a, il-17f et il-23 et procédés d'utilisation de ceux-ci

Also Published As

Publication number Publication date
PT2426144T (pt) 2019-02-06
IL200560A (en) 2013-11-28
CN101687925A (zh) 2010-03-31
JP2010518856A (ja) 2010-06-03
FR18C1051I1 (fr) 2019-02-15
NL300959I2 (en) 2019-01-15
BRPI0807710A8 (pt) 2016-02-10
TR201821029T4 (tr) 2019-01-21
MX2009009079A (es) 2009-08-31
IL200560A0 (en) 2010-05-17
CY2019004I1 (el) 2019-11-27
EP2426144A1 (fr) 2012-03-07
CY2019004I2 (el) 2019-11-27
LTC2059534I2 (lt) 2019-10-10
LT2426144T (lt) 2018-12-10
BRPI0807710B1 (pt) 2021-12-14
ES2708988T3 (es) 2019-04-12
HK1127864A1 (en) 2009-10-09
DK2059534T3 (da) 2012-08-06
ZA200906224B (en) 2010-07-28
AR065420A1 (es) 2009-06-03
US20100272731A1 (en) 2010-10-28
ES2388837T3 (es) 2012-10-19
NZ579158A (en) 2012-01-12
JP2012135319A (ja) 2012-07-19
KR20090114459A (ko) 2009-11-03
SI2426144T1 (sl) 2019-02-28
RS52345B (sr) 2012-12-31
US9809648B2 (en) 2017-11-07
EP2426144B1 (fr) 2018-10-31
JP6054898B2 (ja) 2016-12-27
HUS1800045I1 (hu) 2018-12-28
JP2017060482A (ja) 2017-03-30
US20110142853A1 (en) 2011-06-16
NO2018040I1 (no) 2018-11-15
KR101520110B1 (ko) 2015-05-18
FR18C1051I2 (fr) 2019-12-27
EP2059534A1 (fr) 2009-05-20
HRP20182174T1 (hr) 2019-02-22
CN101687925B (zh) 2012-10-31
US8293883B2 (en) 2012-10-23
AU2008218968A1 (en) 2008-08-28
LTPA2018015I1 (lt) 2019-01-10
US20130122009A1 (en) 2013-05-16
JP5014521B2 (ja) 2012-08-29
RS58098B1 (sr) 2019-02-28
DK2426144T3 (en) 2019-01-07
JP2012228259A (ja) 2012-11-22
WO2008103432A1 (fr) 2008-08-28
JP2014128278A (ja) 2014-07-10
US8404813B2 (en) 2013-03-26
PL2059534T3 (pl) 2012-09-28
PT2059534E (pt) 2012-07-17
CA2678749A1 (fr) 2008-08-28
HRP20120611T1 (hr) 2012-10-31
CY1112912T1 (el) 2016-04-13
BRPI0807710A2 (pt) 2014-05-27
ATE554791T1 (de) 2012-05-15
HUE042172T2 (hu) 2019-06-28
LUC00092I1 (fr) 2018-11-15
CY1121327T1 (el) 2020-05-29
SI2059534T1 (sl) 2012-08-31
AU2008218968B2 (en) 2013-10-17
PL2426144T3 (pl) 2019-05-31
EP2059534B1 (fr) 2012-04-25
CA2678749C (fr) 2018-03-13

Similar Documents

Publication Publication Date Title
FR18C1051I1 (fr)
TWI348451B (fr)
CN300921466S (zh) 型材(34)
CN300727421S (zh) 轮椅电力驱动装置
CN300728932S (zh) 床头柜(90)
CN300728918S (zh) 餐台(7660)
CN300728782S (zh) 墙纸(41)
CN300728744S (zh) 礼品包装纸(21)
CN300728687S (zh) 旅行包(27)
CN300728457S (zh) 汽车前大灯(1475)
CN300728287S (zh) 型材(单推拉窗边封)
CN300726100S (zh) 扇托(2)
CN300905930S (zh) 上衣(053)
CN300728116S (zh) 滑板车(二)
CN300727851S (zh) 滚轮橡皮
CN300727611S (zh) 打印机
CN300728161S (zh) 刀闸阀(无凹槽)
CN300729199S (zh) 桶(2)
CN300729240S (zh) 手柄(锯架2)
CN300726481S (zh) 柜子(四门hd1006)
CN300726322S (zh) 椅子(2)
CN300726316S (zh) 椅子(yfb810)
CN300726313S (zh) 升降转椅(十边)
CN300727339S (zh) 摩托车座垫
CN300727410S (zh) 汽车用后门